variable degree of perivascular inflammation [6] . Circulating cells and their mediators have also been hypothesized to be involved in disease progression because they are capable of promoting recruitment, retention and differentiation of circulating monocytic cell populations that contribute to vascular remodeling [7] .
Monocrotaline (MCT) is an 11-membered macrocyclic pyrrolizidine alkaloid that leads to proliferative pulmonary vasculitis, PAH and cor-pulmonale. MCT induced PAH is commonly used as an animal model of human PAH. MCT is activated to a reactive metabolites in the liver and reactive hepatic metabolites [8] .
Previous investigators have reported that when it is administered in rats it induces ET injury and causes progressive pulmonary vascular changes and right ventricular hypertrophy (RVH) [8] .
Statins, which is 3-hydroxy-3-methylglutaryl coenzyme and a reductase inhibitors, have been used to treat for cardiovascular disease. Initially, the effect of statins was known to lead to lipid reduction. Statins also have varied immunomodulatory and antiinflammatory effects on endothelial and smooth muscle cell seperating from their lipid-lowering ability [9] . Simvastatin limits RhoA/ROCK activity in the chronic hypoxia-exposed lung, thus preventing or ameliorating hemodynamic and structural markers of chronic PAH and improving long-term outcome, without causing adverse effects [10] . The beneficial effects of simvastatin on the development of PAH secondary to left ventricular dysfunction have been noted [11] . However, there has been controversial effect of simvastatin in PAH. Anand et al. [12] reported that statins were not beneficial in the treatment of PAH.
Microarray technology allows the expression and analysis of thousands of genes simultaneously [13] . Initially it was used to verify the molecular basis of cancer and the biological behavior of tumors. It is also a high throughput technique that has played a role in the understanding of the molecular basis of PAH because it can take a broad and relatively unbiased look at the gene expression changes that are presented in human and animal models of disease. Microarrays are a powerful and effective tool in the detection of genome-wide gene expression differences. They have been widely applied in the investigation of the pathobiology of many forms of PAH [14] . There is rare report about RVH associated genes in pulmonary hypertensive rat model after simvastatin treatment. The objective of this study was to investigate altered gene expressions associated RVH in MCT-induced PAH rat hearts after simvastatin.
Methods

Experimental animals
Six-weeks-old male Sprague-Dawley rats, weighing approximately 250 g, were used for this study. 
Measurements
Body weight, right ventricle (RV), left ventricle (LV) and septum, lung and kidney were measured. RV/LV+septum weight ratio was also estimated. The catheter was placed in the RV to estimate the mean right ventricular pressure (RVP).
3. Heart microarray analysis 1) Preparation of fluorescent DNA probe and hybridization Total RNA was extracted from the rat heart tissue using the 
Results
Changes in heart weight and right ventricular pressure
Total body weight of rats has decreased significantly in the M group than the C group. The S group also showed significant decrease in the total body weight of rats. The RV weight has significantly increased in the M group and in the S group.
The LV and septum weight has significantly decreased in the M group at day 28 and there was no significant change in the S group. The RV/LV+septum weight ratio has significantly increased in the M group at day 28. The RV/LV+septum weight ratio has significantly decreased in the S group compared with the M group (Table 1) . RVP has significantly increased in the M group, but the RVP was significantly decreased in the S group compared with M group (Table 1) .
Microarray analysis after simvastatin treatment 1) Total gene heat map
The expression profile of the genes that showed differential expression by more than 1.5-fold (P<0.05) is shown. The red color indicates overexpression while green indicates underexpression ( Fig. 1 ).
2) Intensity ratio histograph
Intensity ratio histograph showed the number of genes according to the expression level changes using log intensity. X- We compared the M group and the S group with the C group.
The M group had 25 different gene expressions and the S group had 82 different gene expressions. In addition, it should be noted that the change in gene expressions between the S group and the M group was quite significant. Compared to the C group, the number of genes with significant differences of expression in the M group and S group were 25 and 282 respectively. In the S group, the expression of 150 genes showed significant differences compared with the M group (Fig. 2 ).
3) Count of differentially expressed gene
The number of genes with a significant differential expression classified according to the function of the genes is shown in Table 2 . In a simple function analysis, 788 genes of M group were expressed by more than 1.5-fold for control. Of these, In analysis of S group compared with the C group sample, a total of 2,545 genes were differentially expressed by more than In analysis of the S group sample in comparison with the M group, a total of 1268 genes were differentially expressed by more than 1.5-fold in microarray. Of these, 670 genes including the genes associated with regulation of progression through cell cycle such as transforming acidic coiled-coil containing protein 3 (Tacc3), BCL2 apoptosis regulator (Bcl2), inhibin and homeostasis. Genes associated with transcription, translation, cell differentiation and signal transduction were differentially expressed significantly (Table 3) .
5) Changes of ET associated gene expressions by microarray
analysis at week 4 The results of microarray analysis of ET associated genes which showed more than 2-fold differential expression are shown in Table 4 (Table 4 ).
6) Changes of nitric oxide associated gene expressions by microarray analysis at week 4
The results of microarray analysis of NO associated genes are shown in Table 5 Table 5 ).
7) Changes of BNP and troponin I associated gene expressions by microarray analysis at week 4
Microarray analysis of differential expressions of BNP and troponin I associated genes showed that BNP gene was signifi- with the C group while it remained similar in the S group to that of the M group (Table 6 ).
Discussion
In our study, RVH and PAH were developed by intraperitoneal single injection of MCT. We were able to confirm this by increased RVP and RV/LV+septum ratio in MCT induced PAH rat model. We also identified the effect of simvastatin on RVH in this study. The RV weight was significantly decreased in the S group compared with the M group at day 28. The RV/ LV+septum weight ratio had also significantly decreased in the S group compared with the M group.
In our microarray data on the heart tissue, genes with a sig- At first, the RV undergoes an increase in wall thickness and contractility in order to maintain a normal cardiac output and ventriculo-arterial coupling. There is a change in RV remodeling from an adaptive to a maladaptive phenotype as the disease progresses. And, as the PAH deteriorates, the RV remodeling moves from an adaptive to a maladaptive state, including RV dilatation, decreased contractility, and ventriculo-arterial uncoupling [15] .
It depends on the degree of pressure overload, but RVH may progress to a condition of impaired contractile function and heart failure. Unfortunately, this is unlikely to be discerned in the early stages of ventricular remodeling. So, microarray analysis can be a valuable tool to reveal pivotal divergent mRNA expression profiles early in the development of compensated ventricular hypertrophy [15] .
In our research, we selected a number of candidate genes such as ET, NOS, BNP and troponin I. They were found to have a more than 2-fold differential expression by microarray analysis. ET-2, ETR-A, NOS1, NOS3 and BNP genes were significantly decreased after simvastatin treatment in the heart tissues. Several studies have suggested that statins could prevent PAH in MCT-induced PAH rat models.
However, there has been rare reporting about RVH associated genes in pulmonary hypertensive rat model after simvastatin treatment. The purpose of this research is to elucidate the genetic pathophysiology of secondary RVH due to PAH by microarray analysis after simvastatin treatment.
There have been many investigations into the role of specific genes in the pathobiology of PAH which have focused on the balance of vasoconstriction and vasodilation [9] . It has been reported that pulmonary vascular remodeling, associated with increasing mean pulmonary arterial pressure, upregulated expressions of endothelial nitric oxide synthase (eNOS), and ET-1 results in the development of PAH [4, 5] .
Other research has been done to identify the changes of endothelium, smooth muscle cells, and the adventitia/extracellular matrix. This research showed that various genes have a role in the pathogenesis of PAH. Expression of ET-1 was found to be elevated in a number of animal models [4] and in human patients with PAH [12, 13] . In addition, eNOS [5] , VEGF-2, PGIS, 5-lipoxigenase, and several genes are involved in the progression of PAH and have been elucidated [12] .
Oxidative stress and the RhoA/Rho-kinase pathway are also thought to be involved in the pathophysiology of PAH [2, 9] .
Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors with pleiotropic effects [2, 9] . Recent studies have suggested that statins may have potential use in the treatment of PAH [8, 9, 16] . Statin safety and efficacy for use against PAH have been recently verified in vivo. These results seem promising due to the pleiotropic effects of statins [16] . Simvastatin attenuates neointimal thickening of the smooth muscle [10] . 
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Simvastatin is effective in inducing apoptosis in hyperproliferative pulmo nary vascular lesions and could be considered as a potential drug for treatment of human severe PAH. However, there is still controversy on the effect of simvas tatin on PAH.
One explanation for the negative results of atorvastatin treatment may be due to the relatively short duration of the therapy [12] .
There are various microarray studies on both human and animal PAH [13, 15] . There have been gene studies of PAH using human samples such as lung specimen and circulating cells from PAH patients [13, 15] . Mitochondrial dysfunction, inflammation and mutant bone morphogenetic protein receptor 2 are associated with PAH, an incurable disease characterized by pulmonary arterial endothelial cell apoptosis, decreased microvessels and occlusive vascular remodeling [17] . Laumanns et al. [18] found only 773 differentially regulated genes, and then looked for these genes into known signaling pathways. And they focused on the planar cell polarity pathway, containing the RHO kinase.
Chen et al. [2] published that his high-enrichment gene ontol- In addition to these results, we carried out further evaluation about specific genes associated with the progression of PAH. Of these genes, the expressions of ET-1 and ET-2 were increased in the M group compared with the C group, but there was no statistically significant difference. In addition, in the S group compared with the M group, expression of ET-2 gene was decreased. This, also, was not statistically significant. ET-1 activates both ETA and ETB-receptors, and it stimulates the production of cytokines and growth factors in response to oxidized LDL, angiotensin II [10, 19] . ET-1 stimulates interleukin and tumor necrosis factor-a expressions in monocytes, leukocyte adherence, platelet aggregation, and adhesion molecule expression.
ET-1 stimulates the production and action of growth factors, DNA and protein synthesis, and cell cycle progression. Increased expressions of ET-1 and ET-2 in the MCT induced PAH rats supports these hypothesis.
We next examined whether the beneficial effect of simvastatin on the expressions of eNOS gene in the heart tissues. Expressions of NOS 1 and 3 were significantly decreased in the S group compared to the M group. This finding may be explained by the stabilizing of increased expressions of eNOS in MCT induced PAH.
NO, is synthesized by 3 subtypes of NO synthase (eNOS, iNOS, and nNOS) and relaxes smooth muscle, inhibits neutrophil and platelet activation and adhesion, and attenuates smooth muscle cell proliferation [20] . Some study groups have found increased NO production, enhanced NO-dependent vasodilation, and a NO-mediated attenuation of resting vascular tone in hypoxia-induced hypertensive rat lungs [21, 22] . Increased expression of eNOS mRNA and protein have also been observed [23] [24] [25] . In other observations [5] , the expressions of NOS gene in MCT induced PAH rats were increased similarly to that in hypoxia-induced hypertensive rat lungs. In our data, expressions of NOS genes were increased in MCT induced PAH rats.
However, that result was not statistically significant, probably due to limited samples of heart tissue.
Simvastatin may have therapeutic potential for preventing and attenuating the development of PAH in RV dysfunction and LV dysfunction through the Rho-kinase pathway and NADPH oxidase [2] . A translational study in humans is needed to substantiate these findings.
Simvastatin attenuated the mean pulmonary artery pressure, pulmonary arteriolar remodeling [16] , The main mechanisms of statins appear to be restoration of endothelial function, attenuation of pulmonary vascular remodeling, regulation of gene expression, regulation of intracellular signaling processes involved in PAH, anti-inflammatory responses, and synergy with other targeted drugs [16] .
The current gold standard for diagnosing PAH and monitoring efficiency of treatment is right heart catheterization. As an alternative, serum biomarkers can also be used. Cardiac troponin T, BNP, and NT-proBNP seem to have the most potential.
BNP is synthesized by cardiac myocyte and their production is increased by factors that increase cardiac pressure and volume.
Also, BNP levels correlate with mean pulmonary artery pressure, right atrial pressure, and total pulmonary resistance [26] .
In our data, expressions of BNP were significantly increased in the M group compared with the C group and were decreased in the S group compared with the M group. It matched well with RV pressure and RV weight in each group. Simvastatin treatment resulted in decreased BNP expression. NT-proBNP showed a correlation with mortality and might have a prognostic value in PAH [27] .
Troponin I is one of three distinct gene products and prevents contraction in the absence of Ca 2+ binding to troponin C and troponin T. These troponins play an important role in regulating excitation-contraction coupling in the heart. And expressions of these gene products are precisely regulated during development and in response to myocardial injury and hemodynamic stress [28] . Troponin I was significantly increased in the M group compared with the C group. However, there was no significant difference in the expression of troponin I between the M and S group in our study.
Several genetic, molecular, biochemical, and environmental factors may explain the variable expressivity of PAH and may contribute to its aggravation or acceleration. Severe PAH seems to represent the far end of a spectrum, in which there is an augmented burden of vascular injury and dysregulated repair [29] . Our result will be helpful to understand the underlying molecular mechanisms of the failing RV in PAH.
This study is preliminary study for searching for the candidate genes associated with RVH. Limitation of this study is that sample size is small. We did not estimate westesternblot analysis.
In the future, we plan to perform westernblot analysis on the protein levels of several genes associated with RVH.
In conclusion, administration of simvastatin in MCT induced PAH rats attenuated the progress of PAH. Microarray analysis showed the altered expression of various genes. This study plays a role as a screening for further investigation about the specific gene expression in PAH rat heart.
